Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × toripalimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 34 Carcinoma, Non-Small-Cell Lung 25 Esophageal Squamous Cell Carcinoma 20 Squamous Cell Carcinoma of Head and Neck 18 Carcinoma, Hepatocellular 17 Triple Negative Breast Neoplasms 16 Breast Neoplasms 15 Advanced Solid Tumor 14 Stomach Neoplasms 13 Melanoma 12 Colorectal Neoplasms 12 Uterine Cervical Neoplasms 11 Small Cell Lung Carcinoma 11 Neoplasms 10 Recurrence 9 Carcinoma, Transitional Cell 8 Carcinoma, Renal Cell 7 Solid Tumor 6 Sarcoma 6 Neoplasm Metastasis 6 Liver Neoplasms 6 Head and Neck Neoplasms 6 Rectal Neoplasms 4 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Esophageal Neoplasms 4 Ovarian Neoplasms 3 Lymphoma 3 Locally Advanced Rectal Cancer 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡